Related Experiment Video

Updated: Aug 8, 2025

Screening Bioactive Nanoparticles in Phagocytic Immune Cells for Inhibitors of Toll-like Receptor Signaling
09:51

Screening Bioactive Nanoparticles in Phagocytic Immune Cells for Inhibitors of Toll-like Receptor Signaling

Published on: July 26, 2017

12.5K

Trial watch: Toll-like receptor ligands in cancer therapy

Julie Le Naour1,2, Guido Kroemer1,3

  • 1Centre de Recherche Des Cordeliers, Equipe Labellisée Par la Ligue Contre le Cancer, Université de Paris Cité, Sorbonne Université, Inserm U1138, Institut Universitaire de France, Paris, France.

Oncoimmunology
|March 6, 2023
PubMed

Insights

Toll-like receptor (TLR) agonists are potent immune adjuvants for cancer immunotherapy. Recent advances show their combination with other therapies and targeted delivery enhance anticancer immune responses.

Area of Science:

  • Immunology
  • Oncology
  • Pharmacology

Background:

  • Toll-like receptor (TLR) agonists are increasingly recognized for their role in restoring cancer immunosurveillance.
  • Three TLR agonists are currently approved for oncological applications, with ongoing extensive research.

Purpose of the Study:

  • To summarize recent preclinical and clinical advancements in the development of TLR agonists for cancer immunotherapy.
  • To highlight the potential of TLR agonists as key components in novel cancer treatment strategies.

Main Methods:

  • Review of preclinical studies investigating TLR agonist efficacy in cancer models.
  • Analysis of clinical trial data evaluating TLR agonists in combination therapies.
  • Examination of novel drug delivery systems, including antibody-conjugated TLR agonists.

Main Results:

  • TLR agonists demonstrate significant immune-activating effects in preclinical and translational studies.
  • Combinations of TLR agonists with chemotherapy, radiotherapy, and other immunotherapies are under active clinical investigation.
  • Targeted delivery of TLR agonists to the tumor microenvironment shows promise for enhanced specificity and efficacy.

Conclusions:

  • TLR agonists are effective immunological adjuvants with broad potential in cancer immunotherapy.
  • Ongoing research and clinical trials are expanding the therapeutic applications of TLR agonists.
  • Future directions include optimizing targeted delivery and combination strategies for improved patient outcomes.
Keywords:
Immunotherapyampligenantibodyimmune checkpoint blockersvidutolimod

More Related Videos

Using X-ray Crystallography, Biophysics, and Functional Assays to Determine the Mechanisms Governing T-cell Receptor Recognition of Cancer Antigens09:53

Using X-ray Crystallography, Biophysics, and Functional Assays to Determine the Mechanisms Governing T-cell Receptor Recognition of Cancer Antigens

Published on: February 6, 2017

11.5K
Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

3.5K

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
606
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
2.6K
lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.7K
The Tumor Microenvironment02:17

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.7K
Signal Transduction: Overview01:26

Signal Transduction: Overview

Cells respond to many types of information, often through receptor proteins positioned on the membrane. They respond to chemical signals, such as hormones, neurotransmitters, and other signaling molecules, initiating a series of molecular reactions to produce an appropriate response. This is called signal transduction. Cells also coordinate different responses elicited by the same signaling molecule via mediators, allowing molecular cross-talk.
Typically, signal transduction involves three...
8.7K